Journal
Blood Advances
Publication Date
1-10-2023
Volume
7
Issue
1
First Page
88
Last Page
91
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2022008634
Rights and Permissions
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Adv. 2023 Jan 10;7(1):88-91. doi: 10.1182/bloodadvances.2022008634. © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Epperla, Narendranath; Shea, Lauren; Bartlett, Nancy L; and et al., "Postibrutinib relapse outcomes for patients with marginal zone lymphoma." Blood Advances. 7, 1. 88 - 91. (2023).
https://digitalcommons.wustl.edu/oa_4/1371
Additional Links
Supplemental material is available for this article at publisher site.
